Oscar Health (NYSE:OSCR) shares climb following Q2 results, but outlook signals loss in second half

Key Facts: - Oscar Health shares have surged in early October 2025, recently trading around $21–22ts2.techmarketbeat.com. The stock hit about $21.50 on Oct 3 and was trading near $21.76 on Oct 14ts2.techmarketbeat.com. - Oscar announced a $410 million convertible debt offering in September 2025 to fund AI-driven technology and growth initiativests2.tech. Proceeds will back “strategic initiatives focused on AI” and expansion of member servicesbusinesswire.comts2.tech. - The company also forged a major partnership with Midwestern grocer Hy‑Vee: launching “Hy‑Vee Health with Oscar”, an employer health plan in Iowa. CEO Mark Bertolini quipped coverage should be “as easy as buying milk at Hy‑Vee”ts2.techbusinesswire.com. - In Q2 2025 Oscar’s revenue jumped ~28–30% YoY to about $2.86–2.9 billion, but losses widened: a $228 million net loss on a high 91.1% medical-loss ratiots2.techts2.tech. Full‑year 2025 revenue guidance was raised to ~$12.0–12.2 B with an expected operating loss of $200–300 M, as Oscar adjusts pricing for higher claim coststs2.techts2.tech. - Wall Street remains cautious. No analysts rate OSCR a “Buy” – the consensus is “Strong Sell” with an average 12‑month price target of only ~$12ts2.techts2.tech. Major firms like UBS, Wells Fargo and Barclays have set low targets and warned of ACA market headwindsts2.techts2.tech. - Policy tailwinds